Unique ID issued by UMIN | UMIN000010560 |
---|---|
Receipt number | R000012275 |
Scientific Title | Research on the preventive effect of the atrial fibrillation by febuxostat |
Date of disclosure of the study information | 2014/04/01 |
Last modified on | 2013/04/22 14:00:04 |
Research on the preventive effect of the atrial fibrillation by febuxostat
Research on the preventive effect of the atrial fibrillation by febuxostat
Research on the preventive effect of the atrial fibrillation by febuxostat
Research on the preventive effect of the atrial fibrillation by febuxostat
Japan |
Paroxysmal atrial fibrillation
Cardiology |
Others
NO
The purpuse of this research is verifing whether febuxostat prevent the incidence of atrial fibrilation via reduction of cardiac oxidative stress
Efficacy
Reduction of incidence of atrial fibrillation
Shortning of duration of atrial fibrillation
Observational
20 | years-old | <= |
Not applicable |
Male and Female
(a) Hyperuricemia (serum urinaric acid level is over 7.0 mg/dl)
(b) The patient with apparent attakck of paroxysmal atrial fibrillation
(c) The patient aged 20 and over in the time of consent acquisition
(d) The document consent by a free intention was obtained.
(e) An outpatient and an inpatient
(a) persistent and permanent AF
(b) The patient who was new-prescribed in an ACE inhibitor or ARB within six months recently. A patient who had the quantity of an ACE inhibitor or ARB increased within six months.
(c) The patient who has mitral stenosis more than the degree of moderate class
(d) The patient who received catheter ablation during less than three months or research period.
(e) The patient already medicated with allopurinol.
(f) A patient with the past of the hypersensitivity to the medicine
(g)The patient who has liver disease (AST or ALT >100U)
(h)The patient who has a severe renal failure (BUN >30mg/dL, Serum creatinin >2.5mg/dL)
(i) The patient under administration of azathioprine, vidarabine and didanosine (contraindications)
(j) A woman under pregnancy or with the possibility of pregnancy
(k) The woman under breast-feeding
(l) The patient who received medication of other trial drugs within three months before the medication
(m) In addition, the patient who judged that a chief (assignment) researcher was unsuitable as a subject
60
1st name | |
Middle name | |
Last name | Hirotaka Yada |
National defense medical college
Cardiology
3-2 Namiki, Tokorozawa, Saitama, Japan
1st name | |
Middle name | |
Last name |
National defense medical college
Cardiology
04-2995-1511
Cardiology, National defense medical college
TEIJIN PHARMA
Other
NO
防衛医科大学校病院 (埼玉県)
2014 | Year | 04 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2012 | Year | 12 | Month | 10 | Day |
2013 | Year | 04 | Month | 22 | Day |
We check blood pressure, pulse rate, blood test, a urine test, chest X-rays, 12 leads electrocardiogram, UCG, the Holter electrocardiogram, and all the efficacy evaluation items of the questionnaire of an arrhythmic attack at the time of a medical treatment start, 6 or 12 months.
2013 | Year | 04 | Month | 22 | Day |
2013 | Year | 04 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012275
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |